Oruka Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share data)
| Year Ended December 31, 2025 | Period from February 6, 2024 (inception) to December 31, 2024 | |
|---|---|---|
| Operating expenses: | ||
| Research and development(1) | $100,640 | $75,060 |
| General and administrative(2) | 21,411 | 13,063 |
| Total operating expenses | 122,051 | 88,123 |
| Loss from operations | (122,051) | (88,123) |
| Other income (expense): | ||
| Interest income | 16,630 | 5,863 |
| Interest expense(3) | — | (1,468) |
| Other income (expense), net | (12) | 4 |
| Total other income, net | 16,618 | 4,399 |
| Net loss | $(105,433) | $(83,724) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.85) | $(3.87) |
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $— | $(3,873.25) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(154.03) | $(322.81) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 45,614,142 | 16,789,362 |
| Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | — | 495 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | 51,946 |
| (1) | Includes related party amounts of $17,129 and $42,640 for the year ended December 31, 2025 and for the period from February 6, 2024 (inception) to December 31, 2024, respectively |
| (2) | Includes related party amounts of $139 and $1,364 for the year ended December 31, 2025 and for the period from February 6, 2024 (inception) to December 31, 2024, respectively |
| (3) | Includes related party amounts of nil and $1,468 for the year ended December 31, 2025 and for the period from February 6, 2024 (inception) to December 31, 2024, respectively |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.